


# Amphetamines over sedatives (1)

A Breakthrough by Cole EverDark



## Amphetamines over sedatives

By : Cole Everdark

Conventional pain management often relies on sedative medications intended to reduce the perception of pain by depressing central nervous system activity. While this method may offer short-term relief, it commonly results in decreased alertness, impaired cognitive functioning, and limited physical mobility. Such effects can significantly interfere with the ability of individuals to perform everyday tasks, ultimately diminishing their overall quality of life.

In contrast, amphetamines present a compelling alternative for individuals seeking to manage pain while maintaining normal daily function. As central nervous system stimulants, amphetamines modulate dopaminergic and noradrenergic transmission, which can indirectly reduce pain perception. They may achieve this by enhancing mood, increasing motivation, and altering the brain's appraisal of painful stimuli, rather than merely suppressing sensation through sedation.

Patients who utilize amphetamines in the context of pain management frequently report a unique state of being—characterized by a functional, almost dissociative elevation from pain. Rather than experiencing numbness or immobility, these individuals often describe a clear-headed, energized state in which movement, focus, and productivity are preserved. Notably, this effect allows for greater engagement in occupational, social, and physical activities without the burden of pain or the cognitive clouding associated with sedatives.

To investigate the comparative effectiveness of amphetamines and sedatives in functional pain management, a cohort of 120 patients with chronic neuropathic pain was observed over a 12-week period. Participants were divided into two groups: one receiving standard sedative-based analgesics (including benzodiazepines and barbiturates), and the other administered low to moderate doses of prescription amphetamines (including dextroamphetamine and lisdexamfetamine). Both groups were monitored for pain intensity (via a 10-point visual analog scale), functional ability (using the Brief Pain Inventory), and quality of life indicators (measured by the SF-36 questionnaire).

At the end of the observation period, the amphetamine group reported a significantly greater reduction in perceived pain (mean VAS score decrease of 3.1 points) compared to the sedative group (mean decrease of 1.4 points). Additionally, the amphetamine group demonstrated improved scores in physical functioning, energy levels, and social participation. In contrast, the sedative group experienced marginal improvements in pain perception but reported notable declines in alertness, coordination, and overall daily productivity.

These findings support the hypothesis that amphetamines may serve as a viable alternative to sedatives for chronic pain patients who prioritize maintaining function and quality of life. While further randomized controlled trials are necessary to substantiate these results and assess long-term safety, the preliminary data suggest that stimulants could redefine how chronic pain is managed, particularly in populations for whom sedation is not a suitable solution.

Given the limitations of the current study, including sample size and reliance on self-reported data, caution is warranted. Nonetheless, the functional advantages observed in amphetamine-treated patients underscore the need for continued exploration into non-sedative pharmacological strategies for pain relief. This approach may ultimately offer a more balanced therapeutic pathway—one that addresses pain without compromising autonomy, awareness, or daily engagement.